Saturday 17 October 2026
Export PROCF’s income statement to Excel — free account
Sofgen Pharma S.A
PROCF Healthcare Drug Manufacturers Specialty & Generic
0.03
0.00
0.00%
Follow PROCF
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Trend | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 9.84 | 8.99 | 7.99 | 4.45 | 1.95 | 0.50 |
Analyst estimates 2025–2027 Powerpack |
|||
| High | — | — | — | — | 9.86 | 10.43 | 11.98 | 10.20 | 6.70 | 4.95 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 4,900 | 5,500 | 5,000 | 4,500 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.08 | 0.07 | 0.08 | 0.08 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 325 | 331 | 410 | 403 | 424 | 374 | ||||
| Gross margin, % | — | — | — | — | 56.19 | 57.72 | 57.53 | 58.32 | 56.16 | 51.23 | |||||
| EBT | — | — | — | 0 | (10) | 1 | (87) | 48 | 46 | (85) | |||||
| EBT margin, % | — | — | — | 0.00 | (3.07) | 0.26 | (21.27) | 11.84 | 10.85 | (22.63) | |||||
| Net income | — | — | 0 | 0 | (17) | (10) | (101) | 36 | 40 | (68) | |||||
| Depreciation | — | — | — | — | 16 | 16 | 15 | 17 | 18 | 20 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 3.34 | 3.41 | 4.17 | 3.99 | 4.20 | 3.73 | ||||
| Earnings | — | — | — | — | (0.18) | (0.11) | (1.03) | 0.42 | 0.40 | (0.61) | |||||
| Cash flow | — | — | — | — | 0.70 | 0.73 | 0.38 | 0.15 | 1.07 | 0.88 | |||||
| Capex | — | — | — | — | (0.12) | (0.18) | (0.24) | (0.32) | (0.32) | (0.25) | |||||
| Free cash flow | — | — | — | — | 0.58 | 0.55 | 0.14 | (0.17) | 0.74 | 0.63 | |||||
| Book value | — | — | — | 0.00 | 0.00 | (2.62) | (0.39) | (0.37) | (0.01) | (0.52) | |||||
| Shares, m | — | — | — | — | 97 | 97 | 98 | 101 | 101 | 100 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 985.00 | 0.00 | 0.00 | 13.38 | 10.54 | 5.76 | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 2.34 | 1.17 | 1.02 | 0.56 | |||||
| P/B | — | — | — | — | 9.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 2.80 | 1.83 | 1.72 | 1.26 | |||||
| EV/FCF | — | — | — | — | (132.69) | (71.16) | 84.48 | (43.61) | 9.74 | 7.13 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 68 | 71 | 37 | 16 | 108 | 88 | ||||
| Capex | — | — | — | — | (12) | (17) | (24) | (32) | (33) | (25) | |||||
| Free cash flow | — | — | — | — | 56 | 54 | 14 | (17) | 75 | 63 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 0 | (55) | 110 | (107) | (158) | (199) | ||||
| Total debt | — | — | — | — | — | 475 | 262 | 306 | 321 | 275 | |||||
| Net debt | — | — | — | 0 | 0 | 471 | 190 | 263 | 297 | 245 | |||||
| Shareholders’ equity | — | — | — | 0 | 0 | (255) | (38) | (37) | (1) | (52) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (12.61) | (14,108.67) | (3.72) | (21.83) | 8.00 | 8.82 | (15.45) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 18.23 | 29.10 | 2.71 | 15.21 | (17.51) | |||||
| ROE | — | — | — | 0.00 | 0.00 | 8.37 | 266.34 | (189.76) | (213.06) | 258.60 | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2023 · fundamentals updated 28 Sep 2026
Charts ten years each
Sofgen Pharma S.A vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DERM Journey Medical Corporation | $144.7M | — (loss-making) | 91.8× | +23.33% (above 0%: growing) | n/m | −84.08% (below 0%: shrinking) | 66.81% | 2.46% | Compare |
| ORGO Organogenesis | $142.8M | — (loss-making) | — (loss-making) | −56.68% (below 0%: shrinking) | n/m | +10.29% (above 0%: growing) | 45.90% | (116.54%) | Compare |
| CRDL Cardiol Therapeutics Inc. | $138.8M | — (loss-making) | — (loss-making) | — | n/m | +10.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OGI Organigram Global Inc. | $131.4M | 2.0× | 11.4× | +49.28% (above 0%: growing) | n/m | −192.32% (below 0%: shrinking) | 39.16% | 5.04% | Compare |
| BGM BGM Group Ltd. | $114.7M | 144× | 44.9× | −2.59% (below 0%: shrinking) | −85.71% (below 0%: shrinking) | +3.00% (above 0%: growing) | 7.12% | 0.00% | Compare |
| PROCF Sofgen Pharma S.A | $114.0M | 0.1× | 4.0× | +17.28% (above 0%: growing) | n/m | +231.11% (above 0%: growing) | 56.09% | 36.48% | |
| CPIX Cumberland Pharmaceuticals Inc. | $113.0M | — (loss-making) | — (loss-making) | −56.28% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| CLVR Clever Leaves Holdings Inc. | $96.5M | — (loss-making) | — (loss-making) | +5.36% (above 0%: growing) | n/m | +70.31% (above 0%: growing) | (7.46%) | (105.91%) | Compare |
| CTOR Citius Oncology, Inc. | $69.4M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | Compare |
| Median of peers | $123.0M | — | 44.9× | +1.39% | — | +1.50% | 42.53% | (52.95%) |
Sofgen Pharma S.A (PROCF) key facts
- Sofgen Pharma S.A (PROCF) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
- As of October 15, 2026, PROCF traded at $0.03, a market capitalization of $114.0 million.
- Return on equity was 258.6% and debt-to-equity -435.78.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −1.40 (distress zone) for fiscal 2024.